The SECURE trial, a Phase 4 study across multiple centers, demonstrated that IBD patients who achieved clinical remission and switched to CT-P13 from the originator IFX experienced similar serum concentration and ADA levels [12,13]. Here, ADA is linked to inflammatory bowel disease.